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Abstract
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Innovation in medicine is often driven by the observations of imaginative physicians who are
blessed with insatiable curiosity, coupled with the inability to accept technical boundaries, the
status quo of patient care, or the acceptance of procedural morbidity. Few examples illustrate this
truism better than the physician-originated clinical research that transformed the safety of carotid
stent angioplasty over the last 2 decades. Initial clinical application of carotid stenting suggested
that proximal protection may be a better approach to prevent embolic stroke during the angioplasty
procedure. The history of how this innovation was developed is particularly relevant as vascular
surgeons adopt new endovascular therapies. It has been more than 15 years since Dr Juan Parodi
put together a multidisciplinary team of scientists and clinicians to test the “proximal protection”
hypothesis. The goal of this overview was to provide Dr Parodi team’s perspective on the
development of the proximal protection and flow reversal concept to minimize plaque
embolization during carotid stent angioplasty procedures.

1.

Introduction

Author Manuscript

In the early 1990s, vascular surgeons were keenly aware that soft, friable atherosclerotic
plaque encountered during carotid endarterectomy (CEA) procedure would pose a limitation
for endovascular catheter procedures from the groin due to risk of embolization. Dr Jacques
Theron set out to overcome this obstacle by inventing a “triaxial” system with a distal
balloon occlusion catheter centered inside the wire lumen of a balloon-dilating catheter that
could be delivered through a guide or sheath system [1]. Theron’s idea was later iterated and

1Current address: 4779 Collins Avenue, Miami, Florida 33140.
*

Corresponding author. J. Parodi, parodijc@yahoo.com (J. Parodi).

Parodi et al.

Page 2

Author Manuscript

commercialized as the “PercuSurge” device by Medtronic (Minneapolis, MN). The
PercuSurge system included a balloon on the distal end of a 0.014” hypotube that could be
inflated by a removable indeflator, such that the hypotube could substitute for a guide wire,
allowing delivery of therapeutic devices while the carotid remained occluded (Fig. 1).
Aspiration of stagnant embolic debris-laden blood in the proximal internal carotid artery
(ICA) cul-de-sac was then performed with a monorail aspiration catheter. Subsequently, Drs.
Parodi and Schönholz collaborated with Dr Patrick Whitlow from the Cleveland Clinic to
initiate the first PercuSurge trials and coauthored the initial publications describing this
technique [2].
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During the PercuSurge carotid angioplasty procedure, Dr Parodi utilized transcranial
Doppler (TCD) monitoring of middle cerebral artery flow to assess collateral flow during
ICA balloon inflation and to detect distal embolization. From his experience with TCD
monitoring during CEA, the team recognized that TCD monitoring could detect highintensity signals (HITS) representative of emboli and identify the need for a shunt in patients
with an incomplete Circle of Willis and poor collateral flow. It was Dr Parodi’s initial intent
to assess adequacy of contralateral flow during distal balloon occlusion with TCD, but he
was surprised to learn that HITS persisted during distal occlusion (Fig. 2). He postulated this
phenomenon was related to paradoxical embolization from reflux into the external carotid
artery and particle escape into the ipsilateral hemisphere via macrocollaterals. In addition, a
small number of patients experienced intolerance to balloon occlusion of the ICA, resulting
in the need for rapid export of debris to complete a given stage of the procedure. Performing
the procedure in stages during intolerance usually allowed completion of early distal
occlusion cases, but the associated “fire drill” was unpleasant for patients and the
interventional team.
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The limitations of PercuSurge led other physicians to develop ICA filters. Dr Jay Yadav
developed one of the first distal filters and, once again, Dr Parodi was involved with the
early cases and trials using the AngioGuard device along with other clinicians (Fig. 3). Dr
Parodi observed that crossing the carotid lesion with the AngioGuard filter induced showers
of HIT particles migrating to the brain, based on TCD monitoring. The TCD-detected
emboli observed during distal filter protection clinical trials led Dr Parodi to reflect on his
experience with CEA, which had fewer TCD-detected HITS, and explore other procedural
alternatives for carotid artery stenting (CAS). Years before, he had observed flow reversal in
the middle cerebral artery while inserting a shunt into the distal internal carotid during a
CEA procedure, and noted this hemodynamic change was well tolerated in the awake patient
(Fig. 4). This transient flow reversal observed in the operating room led to the hypothesis
that flow reversal could potentially be induced via transcatheter proximal occlusion, be
tolerated by the awake patient, and, during the period of flow reversal, embolic particles
from the carotid plaque would not reach the brain. Dr Parodi then performed the first
operation that induced flow reversal during CAS in 1998. A short incision was made at the
base of the neck in a patient with a high-grade stenosis of the ICA exposing the common
carotid artery (Fig. 5). To ensure an adequate landing zone for the sheath and delivery
system, Dr Parodi’s team marked the carotid bifurcation on the skin using ultrasound
imaging before access. After systemic heparinization, an 8Fr sheath was introduced in the
common carotid artery guided by a guide wire inserted in the external carotid artery (ECA).
Semin Vasc Surg. Author manuscript; available in PMC 2019 March 07.
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A PercuSurge balloon was advanced through the sheath to occlude the ECA. The proximal
carotid artery was then clamped and flow reversal was established during CAS using passive
flow reversal by opening the side port and active flow reversal by pulling suction with a
syringe from the side port of the sheath. This index case and subsequent cases were all done
using continuous TCD monitoring of middle cerebral artery flow and were performed with
or without pre-dilatation of the stenotic ICA lesion, depending on its severity. From the
beginning, an 8-mm Wallstent (Boston Scientific, Marlborough, MA) of varied lengths
based on plaque anatomy was deployed. Dr Parodi was pleased to find that no HITS were
detected and this was the first evidence that the “proximal protection” hypothesis was
correct.
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Dr Parodi then set out to develop a percutaneous flow reversal system inserted from a
femoral artery approach. The project began by developing a long 9Fr sheath with a soft
elastomeric balloon tip, called the ArterioA device (Fig. 6). We insisted on special attention
to balloon shape and design, such that the final pear shape allowed for a “funnel-like” entry
into the sheath to prevent particle collection on the outer edges of the balloon. A long
hypotube with a distal shapeable guide wire and soft occlusion balloon 3 cm from the tip
was developed to access and occlude the ECA. The ECA occlusion system had a two-way
stopcock to keep the balloon inflated.
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During the femoral access design phase, Drs. Bates and Ohki were enlisted to assist with the
animal studies. At that time, Dr Bates was working on a distal filter system that was separate
from the wire, but was concerned about clinical observations reported in the 1960s that
suggested radioisotope–labeled spheres >25 μm injected into the carotid artery would not
traverse into the venous phase and, thus, must be occlusive to the brain arteriolar system [3].
Unfortunately, his initial filter prototypes with sub–50-μm pores obstructed flow and caused
a windsock-like driven distal filter migration during animal studies. Thus, he became
intrigued by Dr Parodi’s flow reversal concept, especially because the team at Wake Forest
had documented that a decrease in cognitive function after cardiopulmonary bypass surgery
was likely due to particles that were <60 μm [4].
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The first flow reversal studies in animal were done at the Charleston Area Medical Center
Research Institute in Charleston, WV, utilizing a swine model. The first three swine were
done on a Saturday afternoon in late 1998 and the objective was to troubleshoot the
prototype balloon-tipped sheaths (at the time known as the Parodi Sheath) and the external
balloon occlusion wire, affectionately called “the PEB” (Parodi External Balloon). Dr Bates
and his team found the system worked beautifully and initially he was able to show
radiopaque lead and platinum particles could be released in the mid carotid and retrieved
with flow reversal. Before starting the third animal, Dr Bates reported the exciting positive
findings from the Parodi device and the early experimental success to Dr Parodi in
Argentina. He also raised concerns about blood loss during passive flow reversal and
discussed how this was improved by adding an empty intravenous bag to the sheath port.
However, during the break while waiting for the third case, it occurred to Dr Bates that it
might be possible to take advantage of the natural gradient and attach the Parodi guide
catheter to a venous sheath. One of the technicians went to the hospital perfusion team and
obtained a male-to-male adapter that allowed this simple connection to be made. Later that
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night, Dr Bates added a filter because lead particles could be found in the lungs after flow
reversal testing with the arteriovenous shunt and there would always be the inherent risk of
paradoxical embolization if a PFO were present. The next set of animals done by Dr Bates
included additional testing of flow patterns with a Doppler flow wire in the pig carotid [5].
At the same time Dr Bates was doing additional animal studies with the final design, Dr
Takao Ohki was doing elegant well-controlled canine studies [6]. Of note is that Dr David
Chang, who was a founder of Silk Road Medical (Sunnyvale, CA), was a vascular fellow at
Montefiore Medical Center at this time, and assisted Dr Ohki in performing these Parodi
protection canine studies, perhaps leading to his enthusiasm about the concept. In addition,
Dr Ohki had already redefined how protection device assessment would be conducted with
the invention of an ex vitro model that utilized carotid plaques obtained during CEA [7]. His
model showed that CAS performed in clinically significant plaques generated numerous
emboli and also confirmed Drs Parodi’s and Bates’ concerns about microemboli that were
smaller than current filter pores.
The final device was then ready for clinical trials. Dr Claudio Schönholz was instrumental in
starting the clinical program, and Dr Parodi did the first-in-human transcatheter flow reversal
case in mid-1999. Later that same year, now almost 1 year after the first cervical case, Dr
Schönholz did the second transfemoral case with Dr Parodi. Dr Bates, along with the
engineer-led catheter design team, was present in Argentina for this landmark case.
Angiogram images recorded before and during the carotid stent procedure with flow reversal
in the first patient are shown in Figure 7. The patient was completely asymptomatic and
talking throughout the entire procedure. The device worked well in this case and in all
subsequent cases, but in response to concerns about access in some Type 3 aortic arches, Dr
Parodi modified his 1998 cervical access procedure to involve flow reversal in late 1999.
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In the year 2000, the first article describing cerebral protection during CAS using three
different devices—the Percusurge balloon, the AngioGuard distal ICA filter, and the newly
developed flow reversal system—was published [8]. Dr Parodi reported the first series of
flow reversal cases in 2005 and 2007, including some of his experience outside Argentina
[9]. A flow reversal case performed with Dr Parodi by Dr Doblas in Toledo, Spain may have
contributed to his interest, along with Dr Enrique Criado, to develop the Enroute
Transcarotid Neuroprotection system. Silk Road Medical manufactures this cervical access
flow reversal system and, as noted, was founded by Tony Chou and Michi Garrison based on
work done by David Chang (Dr Ohki’s previous fellow). The device used an 8Fr carotid
sheath placed in the common carotid artery through a small incision at the base of the neck,
which was connected to the common femoral sheath with an interposing filter.
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Dr Parodi’s enthusiasm was infectious, as he began doing cases with pioneering physicians
around the world, including the team in Modena, Italy. Nine months after Dr Parodi filed his
first carotid proximal protection patent (March 13, 1998), Dr Giacchino Coppi in Modena,
Italy filed a patent on a single-unit proximal protection occlusion system (December 3,
1998) known as the MO.MA system. The MO.MA system has also reported excellent results
and is now manufactured and sold by Medtronic [10].
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We formed a company with Dr Gerald Dorros called ArteriA in 1999, which was later
acquired by W.L. Gore and Associates (Flagstaff, AZ), naming it the Gore Flow Reversal
system. Gore proved the efficacy of the system with the EMPiRE trial [11]. Rate of
intolerance to flow reversal was only 2.4%, much lower than with the PercuSurge. We
speculated that this was due to recruitment of pial collaterals. However, Dr Enrique Criado
did a study suggesting the enhanced tolerance of flow reversal with the Silk Road Medical
system was related to enhancing collateral flow from the contralateral hemisphere. In any
event, for the occasional patient with intolerance to flow reversal, we described the “seat belt
and air bag technique,” which combines the use of flow reversal and a filter in 2002 [12].
Flow reversal was used when crossing the lesion with a filter and then the rest of the
procedure was done under filter protection. Claudio Schönholz and his group from the
Medical University of South Carolina compared TCD findings in patients undergoing CAS
with flow reversal to filter-protected stenting showing significant reduction of HITS with
flow reversal [13]. Paradoxically, as data began to surface showing reduced stroke rates,
decreased HITS with TCD, and reduced post-stent abnormalities on diffusion-weighted
magnetic resonance imaging, W.L. Gore made a business decision to discontinue sales of the
Gore Flow Reversal system due to discouraging CAS market forecasts and contracting sales
prices.
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2.

Conclusions
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Results of the application of ICA flow reversal in clinical trials suggest better outcomes than
expected with filters, and many authorities in the field now consider it the most effective
protection device for CAS. During the 2015 Society of Vascular Surgery meeting (Chicago,
IL), Dr Christopher Kwolek presented the ROADSTER (Safety and Efficacy Study for
Reverse Flow Used During Carotid Artery Stenting Procedure) study using the Enroute
Transcarotid Neuroprotection system (Silk Road Medical). Kwolek reported a zero
incidence of stroke in symptomatic patients, as well as patients older than 75 years of age
(one of the most exciting findings to date). During the last 1½ decades, each of the authors
has continued to work on innovations in this domain, resulting in many publications as well
as the acquisition of the Bates patents related to a filter that can be placed after the wire is
already across the lesion. However, throughout that time, the entire flow reversal team has
continued to believe in the initial theory and vision of Dr Parodi. More importantly, each of
us looks back and cherishes the friendships that were forged during the discovery phase of
this project under Dr Parodi’s direction. The CREST 2 (Carotid Revascularization for
Primary Prevention of Stroke) trial will include flow reversal in the endovascular arm and
will hopefully provide level I evidence confirming Dr Parodi’s initial hypothesis. Further
insight into the thinking that led to flow reversal is provided in the editorial entitled “Chance
Favors the Prepared Mind” [14].
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Fig. 1 –.

Schematic and angiographic images of the PercuSurge balloon occlusion embolic protection
device used during carotid stent angioplasty. (A) The balloon is partially inflated in the distal
internal carotid artery (ICA). (B) The balloon is completely inflated and no contrast is seen
in the ICA, indicating cessation of flow.
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Fig. 2 –.
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Transcranial Doppler waveform recorded from the middle cerebral artery showing a shower
of high-intensity signals (HITS) during a carotid artery stenting (CAS) procedure. The
embolic HITS were observed during distal protection CAS procedure using the PercuSurge
device or with deployment of a filter device in the internal carotid artery.
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Fig. 3 –.

Schematic of the Angioguard filter device deployed in the distal internal carotid artery (ICA)
to capture embolic debris during stent angioplasty of the proximal ICA stenosis.

Author Manuscript
Semin Vasc Surg. Author manuscript; available in PMC 2019 March 07.

Parodi et al.

Page 10

Author Manuscript
Author Manuscript
Author Manuscript

Fig. 4 –.

Schematic of shunt insertion in the internal carotid artery during a carotid endarterectomy
procedure with transcranial Doppler waveforms recorded from the middle cerebral artery
(MCA) before (top waveform) showing normal antegrade flow and flow reversal during
shunt insertion (bottom waveform). The patient, who was awake, exhibited no neurologic
signs during or after the flow reversal episode.
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Fig. 5 –.

Operative photo of the first procedure to produce flow reversal during a carotid stent
procedure. A small incision was made at the base of the neck and common carotid artery and
jugular vein were dissected. Introducer catheters were placed in both vessels and then
connected with a tube containing a filter.
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Fig. 6 –.
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Left: Photo of the ArteriA device composed of a 9Fr, 90-cm sheath with a balloon at the end
and a hypotube with a balloon to occlude the external carotid artery. Right: Schematic of
device inserted in the carotid bifurcation with balloon in the external carotid artery.
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Fig. 7 –.

Angiogram images of the first patient treated with internal carotid artery flow reversal. Left:
Before stent placement. Right: After stent placement.
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